Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
17,000
Gilead Sciences Inc News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,853.30 | 70.60 | -0.79% |
| CAC 40 | 8,117.78 | 61.99 | -0.76% |
| DAX 40 | 25,440.81 | 127.75 | -0.50% |
| Dow JONES (US) | 52,421.20 | 152.09 | -0.29% |
| FTSE 100 | 10,697.57 | 47.13 | 0.44% |
| HKSE | 24,818.06 | 99.54 | -0.40% |
| NASDAQ | 26,186.41 | 146.62 | -0.56% |
| Nikkei 225 | 64,004.66 | 511.67 | 0.81% |
| NZX 50 Index | 13,495.27 | 65.42 | -0.48% |
| S&P 500 | 7,619.98 | 37.00 | -0.48% |
| S&P/ASX 200 | 8,671.70 | 78.20 | -0.89% |
| SSE Composite Index | 3,883.24 | 2.10 | -0.05% |